AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · IEX Real-Time Price · USD
8.98
+0.43 (5.03%)
Apr 23, 2024, 4:00 PM EDT - Market closed
AVITA Medical Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for AVITA Medical stock have an average target of 28.25, with a low estimate of 21 and a high estimate of 40. The average target predicts an increase of 214.59% from the current stock price of 8.98.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 23, 2024.
Analyst Ratings
The average analyst rating for AVITA Medical stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 11, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $19 → $21 | Buy | Reiterates | $19 → $21 | +133.85% | Feb 23, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $22 → $25 | Buy | Maintains | $22 → $25 | +178.40% | Feb 23, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $20 → $22 | Buy | Maintains | $20 → $22 | +144.99% | Jan 19, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $20 | Buy | Reiterates | $20 | +122.72% | Nov 21, 2023 |
Financial Forecast
Revenue This Year
81.69M
from 51.57M
Increased by 58.41%
Revenue Next Year
114.14M
from 81.69M
Increased by 39.72%
EPS This Year
-1.13
from -1.40
EPS Next Year
-0.18
from -1.13
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 87.1M | 132.3M | 184.4M | 142.3M |
| Avg | 81.7M | 114.1M | 146.2M | 138.2M |
| Low | 74.1M | 93.2M | 116.9M | 132.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 68.9% | 61.9% | 61.5% | -2.7% |
| Avg | 58.4% | 39.7% | 28.1% | -5.5% |
| Low | 43.7% | 14.1% | 2.4% | -9.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.20 | -0.01 | 1.09 | 0.21 |
| Avg | -1.13 | -0.18 | 0.49 | 0.20 |
| Low | -1.66 | -0.34 | 0.05 | 0.19 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | -57.9% |
| Avg | - | - | - | -59.1% |
| Low | - | - | - | -60.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.